AU2003280558A1 - Method for treatment of cancer - Google Patents

Method for treatment of cancer

Info

Publication number
AU2003280558A1
AU2003280558A1 AU2003280558A AU2003280558A AU2003280558A1 AU 2003280558 A1 AU2003280558 A1 AU 2003280558A1 AU 2003280558 A AU2003280558 A AU 2003280558A AU 2003280558 A AU2003280558 A AU 2003280558A AU 2003280558 A1 AU2003280558 A1 AU 2003280558A1
Authority
AU
Australia
Prior art keywords
cancer
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003280558A
Inventor
Takeshi Doi
Tatsuhiko Kodama
Chikage Mataki
Toshiaki Oda
Masao Ohkuchi
Shunji Takemura
Masahiro Tamura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kowa Co Ltd
Original Assignee
Kowa Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co Ltd filed Critical Kowa Co Ltd
Publication of AU2003280558A1 publication Critical patent/AU2003280558A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
AU2003280558A 2002-10-11 2003-10-10 Method for treatment of cancer Abandoned AU2003280558A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41759802P 2002-10-11 2002-10-11
US60/417,598 2002-10-11
PCT/JP2003/013048 WO2004032933A1 (en) 2002-10-11 2003-10-10 Method for treatment of cancer

Publications (1)

Publication Number Publication Date
AU2003280558A1 true AU2003280558A1 (en) 2004-05-04

Family

ID=32094044

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003280558A Abandoned AU2003280558A1 (en) 2002-10-11 2003-10-10 Method for treatment of cancer

Country Status (2)

Country Link
AU (1) AU2003280558A1 (en)
WO (1) WO2004032933A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006050476A2 (en) 2004-11-03 2006-05-11 Vertex Pharmaceuticals Incorporated Pyrimidine derivatives as ion channel modulators and methods of use
WO2008147864A2 (en) * 2007-05-22 2008-12-04 Xenon Pharmaceuticals Inc. Methods of using piperazine compounds in treating sodium channel-mediated diseases or conditions
US8536186B2 (en) 2008-08-04 2013-09-17 Chdi Foundation, Inc. Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
US7994357B2 (en) * 2009-04-03 2011-08-09 Naturewise Biotech & Medicals Corporation Cinamic compounds and derivatives therefrom for the inhibition of histone deacetylase
RU2012133475A (en) 2010-01-25 2014-03-10 Схди Фаундейшн, Инк. KINURENIN-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND WAYS OF THEIR APPLICATION
SG2014011654A (en) 2011-08-30 2014-08-28 Chdi Foundation Inc Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
PH12017502049A1 (en) 2011-08-30 2018-08-29 Chdi Foundation Inc Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2016011316A1 (en) 2014-07-17 2016-01-21 Chdi Foundation, Inc. Methods and compositions for treating hiv-related disorders
US10905687B2 (en) 2016-10-27 2021-02-02 Escalier Biosciences B.V. Substituted piperazines as ROR-gamma modulators
CN112292124A (en) 2018-03-12 2021-01-29 爱思凯利尔生物科学私人有限责任公司 Bicyclic ROR-gamma modulators
US11242350B2 (en) 2018-03-12 2022-02-08 Escalier Biosciences B.V. Spirocyclic ROR-gamma modulators

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9208740D0 (en) * 1992-04-23 1992-06-10 Glaxo Group Ltd Chemical compounds
JP3808921B2 (en) * 1995-11-20 2006-08-16 興和株式会社 Cell adhesion inhibitor
US6509329B1 (en) * 2001-06-29 2003-01-21 Kowa Co., Ltd. Cyclic diamine compound with 6-membered ring groups
US6552188B2 (en) * 2001-06-29 2003-04-22 Kowa Co., Ltd. Unsymmetrical cyclic diamine compound
US6432957B1 (en) * 2001-06-29 2002-08-13 Kowa Co., Ltd. Piperazine derivative

Also Published As

Publication number Publication date
WO2004032933A1 (en) 2004-04-22

Similar Documents

Publication Publication Date Title
AU2003226301A1 (en) Method of treating cancer
AU2003256847A1 (en) Method of treating cancer
AU2003224788A1 (en) Method for treatment of tissue
AU2003293333A1 (en) Method of treating cancers
AU2003213771A1 (en) Method for modification of radiotherapy treatment delivery
AU2003259249A1 (en) Pyridazinylpiperazine derivatives for treating pain
AU2003281076A1 (en) Process for treatment of underground reservoirs
AU2002328952A1 (en) Irinotecan for treatment of cancer
AU2002359950A1 (en) Plasma treatment method
AU2003280558A1 (en) Method for treatment of cancer
AU2003223538A1 (en) Methods for the treatment of cancer
AU2003233820A1 (en) Method for the treatment of starch
AU2003222449A1 (en) Medicine for treating cancer
AU2002308642A1 (en) Methods for treating cancer
AU2003218188A1 (en) Method of treating onychomycosis
AU2003259833A1 (en) Methods of treating neurodegenerative diseases
AU2003221005A1 (en) Method of wastewater treatment
AU2003272972A1 (en) Method of treatment for cancer
AU2003296242A1 (en) Thia-epothilone derivatives for the treatment of cancer
AU2002951913A0 (en) Method of treatment
AU2003272973A1 (en) Method for treatment of cancer
AU2003248584A1 (en) Method of treating osteoarthritis
AUPR731901A0 (en) Method of treatment
AU2003252188A1 (en) Method of ore treatment
AU2003236232A1 (en) Method for treatment of textile

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase